GAVI funds advance vaccine procurement for lower-income countries, providing manufacturers with a committed buyer before trials complete. In the Bundibugyo outbreak it has committed $50m in contingent procurement through its First Response Fund.

How is GAVI involved in the H5N1 vaccine trial?

GAVI is responsible for ensuring low- and middle-income countries receive any authorised H5N1 vaccine on a comparable timeline to high-income purchasers, a role it plays via advance purchase frameworks alongside CEPI.Source: GAVI

Is GAVI funded by the US government?

Yes. The US is a significant GAVI donor, though it has at times sought to attach intellectual-property conditions to contributions. GAVI also draws on the UK, EU member states, the Gates Foundation, and the pharmaceutical industry.

Background

GAVI (the Vaccine Alliance) is an international public-private partnership founded in 2000, headquartered in Geneva, that funds vaccine procurement and delivery infrastructure for lower-income countries. It draws on contributions from donor governments, including the UK, US, and EU member states, as well as the Gates Foundation and the pharmaceutical industry. GAVI co-manages the COVAX facility and works alongside CEPI and WHO to coordinate pre-purchase agreements, cold-chain logistics, and regulatory harmonisation in countries that cannot negotiate directly with vaccine manufacturers. It has immunised more than one billion children since its founding and is the primary financing mechanism for introducing new vaccines in the world's 57 lowest-income countries.

On 1 June 2026 GAVI added $50 million in contingent procurement through its First Response Fund for Bundibugyo ebolavirus vaccines, complementing the $62m in CEPI development grants across three platforms announced on the same day. The contingent structure means GAVI commits to purchase doses once a candidate reaches emergency authorisation, providing the commercial signal manufacturers need to scale production before a trial readout. This mirrors the COVAX advance market commitment model that accelerated COVID-19 vaccine procurement, though the Bundibugyo commitment is smaller and concentrated on the active outbreak. GAVI also participates in the WHO R&D Blueprint consultations, contributing a procurement and delivery perspective to pathogen-family roadmaps. The Bundibugyo commitment builds on the $500m pledged at the Africa CDC summit on 26 May 2026, of which GAVI's First Response Fund contribution is part of the equity access architecture. Without advance procurement guarantees, a successful Bundibugyo candidate risks the same 12-to-18-month LMIC access lag that characterised the COVID-19 vaccine rollout.

GAVI's board closed a two-day meeting on 2 July 2026 by approving an additional $189 million for the African Vaccine Manufacturing Accelerator, on top of the programme's existing $1 billion, with $139 million earmarked specifically for procuring Africa-manufactured vaccines and first disbursements expected in the second half of 2026. The same meeting agreed GAVI 6.0, the Alliance's 2026-2030 strategic period, targeting 500 million more children reached and 8-9 million deaths prevented, the funding envelope within which its Bundibugyo First Response Fund commitment now sits.

More questions

What is GAVI's First Response Fund?

GAVI's First Response Fund is a mechanism for rapid contingent vaccine procurement during active outbreaks. It committed $50m for Bundibugyo ebolavirus vaccines on 1 June 2026, providing manufacturers a committed buyer once a candidate reaches emergency authorisation.Source: GAVI

What is GAVI and how does it fund vaccines?

GAVI is the Vaccine Alliance, a public-private partnership founded in 2000 and headquartered in Geneva. It funds vaccine procurement and delivery for the world's 57 lowest-income countries through advance purchase agreements, cold-chain support, and regulatory harmonisation.

What is GAVI doing about the Ebola outbreak in DRC in 2026?

On 1 June 2026 GAVI committed $50 million in contingent procurement through its First Response Fund for any Bundibugyo ebolavirus vaccine that reaches emergency authorisation, covering all four candidates in CEPI's $63.7m portfolio.Source: GAVI / CEPI

How does GAVI's advance purchase commitment work?

GAVI's contingent procurement commits to buying doses once a vaccine candidate reaches emergency authorisation, giving manufacturers the commercial signal to scale production before a trial readout. It mirrors the COVAX advance market commitment model used during COVID-19.

Why did COVID-19 vaccines reach poorer countries later than rich ones?

High-income countries pre-booked vaccine supplies directly with manufacturers under bilateral deals, leaving low-income countries dependent on the COVAX facility, which received deliveries 12-18 months later. GAVI's advance procurement role for Bundibugyo aims to prevent the same outcome.

Source Material

Gavi Alliance (Wikipedia)GAVI — Wikipedia GAVI — The Vaccine Alliance

How the World Sees Them

United States

The US provides significant GAVI funding but has at times sought to condition contributions on intellectual-property provisions, creating tension over GAVI's mandate to negotiate lower-price access.

European Union

EU member states are among GAVI's largest donors and view GAVI as a geopolitical instrument for health diplomacy alongside the development financing motive.

Sub-Saharan Africa

GAVI is the primary vaccine financing mechanism for most African health ministries; its First Response Fund commitment is essential to ensuring any authorised Bundibugyo vaccine reaches DRC and Uganda health workers.